EGFR and neoplasm: The mechanism of osimertinib is that the acrylamide contained in osimertinib can form the covalent bonding with C797 at the edge of the ATP binding site in the catalytic domain of the EGFR gene, and then the irreversible binding occurs with the specific EGFR mutations, to solve the problem of abnormal signal transduction pathway in downstream cells caused by EGFR mutation, inhibit the excessive proliferation and mutation of tumor cells due to the EGFR mutation, and reduce the metastasis rate.